Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Inventory: 2011-2025

Historic Inventory for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $11.9 million.

  • Ligand Pharmaceuticals' Inventory fell 28.91% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 28.91%. This contributed to the annual value of $14.1 million for FY2024, which is 41.12% down from last year.
  • Ligand Pharmaceuticals' Inventory amounted to $11.9 million in Q3 2025, which was down 23.17% from $15.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Inventory high stood at $39.9 million for Q2 2021, and its period low was $11.9 million during Q3 2025.
  • Moreover, its 3-year median value for Inventory was $16.7 million (2024), whereas its average is $18.5 million.
  • In the last 5 years, Ligand Pharmaceuticals' Inventory skyrocketed by 979.04% in 2021 and then tumbled by 51.35% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Inventory (Quarterly) stood at $27.3 million in 2021, then plummeted by 51.35% to $13.3 million in 2022, then surged by 80.30% to $24.0 million in 2023, then tumbled by 41.12% to $14.1 million in 2024, then dropped by 28.91% to $11.9 million in 2025.
  • Its Inventory was $11.9 million in Q3 2025, compared to $15.5 million in Q2 2025 and $14.6 million in Q1 2025.